Andrew Armstrong, MD, Professor of Medicine and Surgery at Duke University and lead author of this research. "This is the first-ever AI-derived biomarker that can predict clinical benefit from longer-duration therapy," said Dr. Andrew Armstrong, MD, Professor of Medicine and Surgery at Duke University, sought to develop an AI-based predictive biomarker to address this unmet need. The authors of the research, including Dr. To help guide a treatment plan that will maximize benefits and minimize risks, predictive biomarkers are needed. When making treatment decisions, clinicians and patients must consider the duration of therapy, which is known to have a wide range of negative side effects. In patients with high-risk localized prostate cancer, ADT is considered a cornerstone of treatment, along with radiotherapy. The biomarker demonstrated the ability to predict the benefit of long-term androgen deprivation therapy (ADT) in men with localized high-risk prostate cancer. SAN FRANCISCO, June 01, 2023-( BUSINESS WIRE)- ArteraAI, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announces new data validating a multimodal AI-derived predictive biomarker, which has been selected as an oral presentation at the 2023 ASCO annual meeting. The biomarker is the first to predict long-term ADT usage in men with high-risk localized prostate cancer
0 kommentar(er)
